High-risk prostate cancer treatment before and after surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 18 or older.
- You have been diagnosed with prostate cancer that is considered high-risk or unfavorable intermediate-risk based on your Gleason score (7 or higher, with a pattern of 4+3).
- Your cancer has certain genetic markers (Decipher score above 0.45 or Luminal B subtype) found on your biopsy.
- You have not had chemotherapy or radiation for prostate cancer before.
- You have not had prior treatment with certain prostate cancer drugs (like enzalutamide, abiraterone, or Darolutamide itself) or with immunotherapy drugs (like PD-1/PD-L1 inhibitors).
- You are in generally good health (able to care for yourself and perform daily activities) and have adequate organ function (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This trial tests a new combination of two drugs given before surgery to shrink high-risk prostate cancer. The goal is to see if this approach can improve outcomes for patients whose cancer is aggressive but has not spread.
This study tests whether giving the drug darolutamide (with or without standard hormone therapy) before surgery helps shrink high-risk prostate cancer and reduce the chance of it coming back. If you qualify, you would receive the study treatment for a few months before your planned prostate removal surgery.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.